COVID-19
Conditions
Brief summary
This is a Phase 2/3, randomized, double-blind, placebo-controlled, multi-center study to evaluate the safety, tolerability, and efficacy of ADM03820 to prevent symptomatic COVID-19 in adult subjects (≥ 18 years of age).
Detailed description
Approximately 450 subjects will be enrolled in the Phase 2 segment of the study and will be randomized in a 2:1 ratio with a total of 300 subjects receiving ADM03820 and 150 subjects receiving placebo. In the Phase 3 segment, an additional 4,000 subjects will be enrolled and randomized in a 2:1 ratio, for a total sample size (including the Phase 2 subjects) of 4,450 total subjects. The primary objective of the Phase 2 segment is to evaluate the safety and tolerability of ADM03820 in adult subjects. The secondary objectives are to assess safety, PK, immunogenicity, and microneutralization (MN) of ADM03820 and to gather information surrounding COVID-19 incidence rates and COVID-19 symptoms to support Phase 3 assumptions and assessment of efficacy. The primary objectives of the Phase 3 segment are to evaluate the efficacy of ADM03820 for the prevention of symptomatic COVID-19 in adult subjects. The secondary objectives are to evaluate the efficacy of ADM03820 for prevention and amelioration of COVID-19 symptoms, to monitor the incidence and severity of COVID-19, and to evaluate the safety and tolerability of ADM03820.
Interventions
DRUGADM03820
ADM03820 is a 1:1 mixture of two human IgG1 non-competitive binding anti-SARS-CoV-2 antibodies
OTHERPlacebo
Placebo
Sponsors
Enabling Biotechnologies (EB)
Alachua Government Services, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
Phase 2 Inclusion Criteria: 1. Informed consent understood and signed prior to screening procedures 2. Healthy male or non-pregnant, non-lactating female 18 years of age or older, inclusive on the day of dosing 3. Subject willing to comply with and be available for all protocol procedures for the duration of the study 4. Subject determined by medical history, physical examination, and clinical judgement of the principal investigator (PI) to be eligible for inclusion in the study by meeting all the inclusion criteria and no
Exclusion criteria
5. Subject with BMI ≥18.5 and ≤ 35 kg/m2 6. Females of childbearing potential must have a negative urine pregnancy test on Day 1 prior to dosing Note: A woman is considered of childbearing potential unless post-menopausal (\> or = 1 year without menses without other known or suspected cause and appropriately elevated FSH) or surgically sterilized via bilateral oophorectomy or hysterectomy. 7. Females of childbearing potential and males must agree to use medically effective contraception (methods with a failure rate of \< 1% per year when used consistently and correctly) from screening until last dose. Acceptable methods include: hormonal contraception including implants, injections or oral; two barrier methods, e.g., condom and cervical cap (with spermicide) or diaphragm (with spermicide); intrauterine device or intrauterine system; abstinence when this is the subject's preferred and usual lifestyle. 8. Subject agrees to not donate bone marrow, blood, and blood products for at least 3 months after dosing 9. Clinical laboratory results within normal ranges or are no greater than Grade 1 and deemed not clinically significant by medical monitor and PI. (Any subjects with results that are Grade 2 or above according to toxicity table (modified from FDA Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trial) will be excluded) 10. Subject willing to provide verifiable identification and has means to be contacted and to contact the Principal Investigator (PI) during the study. Phase 2
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of SAEs and medically-attended AEs (Phase 2) | 540 days | Number of participants with SAEs and medically-attended AEs through end of study |
| Occurrence of changes from baseline in physical examination, vital signs, and clinical safety laboratory values (Phase 2) | 365 days | Number of participants with changes from baseline |
| Incidence of symptomatic, virologically confirmed COVID-19 (Phase 3) | Day 1 to Day 29 | Number of participants with symptomatic, virologically confirmed COVID-19 |
| Incidence and severity of reactogenicity through Day 7 and adverse events (AEs) through end of study (Phase 2) | 540 days | Number of participants with AEs and reactogenicity symptoms. FDA Toxicity Grading Scale for Local and General Systemic Reactogenicity will assess severity. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of AEs (Phase 2) | 540 days | Number of participants with AEs through end of the study |
| Incidence of SAEs (Phase 2) | 540 days | Number of participants with SAEs through end of the study |
| Incidence of COVID-19 related medically attended events (Phase 2) | 540 days | Number of participants with events occurring after dosing through end of study |
| The assessment of Cmax for each of the monoclonal antibodies of ADM03820 as measured by mAb specific enzyme-linked immunosorbent assay (ELISA) (Phase 2) | 365 days | Pre-dose and on Days 3, 8, 29, 57, 85, 134, 183, 232, 274 and 365 |
| The assessment of Tmax for each of the monoclonal antibodies of ADM03820 as measured by mAb specific enzyme-linked immunosorbent assay (ELISA) (Phase 2) | 365 days | Pre-dose and on Days 3, 8, 29, 57, 85, 134, 183, 232, 274 and 365 |
| The assessment of AUC(0-t) for each of the monoclonal antibodies of ADM03820 as measured by mAb specific enzyme-linked immunosorbent assay (ELISA) (Phase 2) | 365 days | Pre-dose and on Days 3, 8, 29, 57, 85, 134, 183, 232, 274 and 365 |
| To assess anti-drug antibody levels (Phase 2) | 365 days | Pre-dose and on Days, 85, 134, 183, 232, 274, and 365 |
| To assess daily COVID-19 symptoms (Phase 2) | 183 days | COVID-19 daily symptoms reported by participants in diaries |
| SARS-CoV-2 RT-PCR assay in symptomatic subjects (Phase 2) | 540 days | — |
| Severity of each symptom (Phase 3) | 540 days | Severity of symptoms are assessed from Day 1 through end of study |
| Incidence of mild, virologically confirmed COVID-19 (Phase 3) | 183 days | Number of participants with mild, virologically confirmed COVID-19 through Days 29, 57, 134 and 183 |
| Incidence of moderate, severe, or critical virologically confirmed COVID 19 (Phase 3) | 183 days | Number of participants with moderate, severe, or critical virologically confirmed COVID 19 through Days 29, 57, 134, and 183 |
| Incidence of and severity of virologically-confirmed COVID-19 (Phase 3) | 540 days | Number of participants with virologically-confirmed COVID-19 and severity of symptoms from Days 29, 57, 134, and 183 through Day 540 |
| Incidence of AEs, SAEs, and medically attended events (Phase 3) | 540 days | Number of participants with AEs, SAEs, and medically attended events through end of study |
| To assess SARS-CoV-2 antibody microneutralization levels (Phase 2) | 57 days | Pre-dose and at Days 3, 29, and 57 |
| Incidence of symptomatic, virologically confirmed COVID-19 (Phase 2 and Phase 3) | 183 days | Number of participants with symptomatic, virologically confirmed COVID-19 through Day 183 (Phase 2) and through Day 57, Day 134, and Day 183 (Phase 3) |
| Hospitalization (Phase 2 and Phase 3) | 183 days | Number of hospitalizations |
| All-cause mortality (Phase 2 and Phase 3) | 183 days | Number of all-cause mortality |
Other
| Measure | Time frame | Description |
|---|---|---|
| To assess Anti-SARS-CoV-2 Nucleoprotein (NP) antibody levels (Phase 2 and Phase 3) | 274 days | Baseline and on Days 29, 57, 183 and 274 |
| Collection of cDNA for SARS-CoV-2 sequence from subjects with positive RT-PCR assay (Phase 3) | 540 days | — |
| Serum collection for future analysis (Phase 2 and Phase 3) | 365 days | — |
Outcome results
None listed